-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34

Benzinga·07/10/2026 15:42:49
Listen to the news
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $32 to $34.